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Abstract 
The histological diagnosis of peripheral T-cell lymphoma (PTCL) can represent a challenge, 
particularly in the case of closely related entities like angioimmunoblastic T-lymphoma 
(AITL), PTCL-not otherwise specified (PTCL-NOS), and ALK-negative anaplastic large-cell 
lymphoma (ALCL). Although gene expression profiling and next generations sequencing 
have been proven to define specific features recurrently associated with distinct entities, 
genomic-based stratifications have not yet led to definitive diagnostic criteria and/or entered 
into the routine clinical practice. 
Herein, to improve the current molecular classification between AITL and PTCL-
NOS, we analyzed the transcriptional profiles from 503 PTCLs stratified according to their 
molecular configuration and integrated them with genomic data of recurrently mutated genes 
(RHOAG17V, TET2, IDH2R172, DNMT3A) in 53 cases (39 AITLs and 14 PTCL-NOSs) included 
in the series. Our analysis unraveled that the mutational status of RHOAG17V, TET2 and 
DNMT3A poorly correlated, individually, with peculiar transcriptional fingerprints. Conversely, 
in IDH2R172 samples a strong transcriptional signature was identified that could act as a 
surrogate for mutational status. The integrated analysis of clinical, mutational and molecular 
data led to a simplified 19-gene signature that retains high accuracy in differentiating the 
main nodal PTCL entities. The expression levels of those genes were confirmed in an 
independent cohort profiled by RNA-sequencing.   
 
  












Peripheral T-cell lymphomas (PTCL) represent a heterogeneous group of nodal and extra-
nodal mature T-cell Non-Hodgkin lymphomas (T-NHL) accounting for approximately 10-15% 
of all lymphoma in the Western countries.1 Histological diagnosis of the various PTCL 
subtypes can still represent a challenge and difficulties occur in particular for those samples 
with borderline features between angioimmunoblastic T-cell lymphoma (AITL), follicular T-
cell lymphoma and PTCL not otherwise specified (PTCL-NOS).1,2 Previous studies have 
shown that these entities might bear distinct transcriptional and mutational profiles.3-8 Gene 
expression profiling has the potential to represent the gold standard for classification, but its 
clinical use is still limited due to technical limits and to the absence of a manageable and 
practical short consensus gene signature. Recent advances in next generation sequencing 
(NGS) allowed the discovery of recurrently mutated genes (RHOA, TET2, DNMT3A) in 
approximately 60-70% of AITL and in 20-30% of PTCL-NOS, changing in part this 
landscape.6,9-12 Notably, 20-30% of AITL cases can carry hotspot IDH2R172 mutations that 
are virtually absent in PTCL-NOS.9 Nevertheless, these findings have not yet significantly 
impacted diagnosis in daily clinical practice, which largely relies on morphological and 
immunophenotypic features of tumor cells.1 Moreover, albeit some mutations appear to be 
linked to distinct transcriptional signature(s),6 the full potential of an integrated genotypic-
transcriptomic analysis has not been thoroughly tested in PTCLs. Herein, we collected a 
large gene expression profiling dataset of PTCLs, and performed an integrative analysis with 
available mutational data to improve our understanding of the underlying structure of sample 
clusters, with potential implications for disease classification particularly at the interface 




We analysed 503 PTCL, univocally acquired from 8 studies (GSE6338, GSE14879, 
GSE19067, GSE19069, GSE58445 and GSE65823 at http://www.ncbi.nlm.nih.gov/geo/; 











ETABM702 and ETABM783 at https://www.ebi.ac.uk/arrayexpress, Supplementary Figure 
1). Normalized data were extracted using RMA procedure and the annotation available at 
http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/21.0.0/entrezg.asp. 
A batch-effect correction was applied using ComBat function in sva package for R software. 
The whole data set with all available clinical and genomic information acquired was 
uploaded to https://github.com/emacgene/PTCL.  
 
Transcriptional and statistical analysis 
The statistical models that allow measuring the association between mutations and gene 
expression was firstly described in Gerstung et al.13 and here adapted to 39 AITLs and 14 
PTCL-NOSs for whom mutational data for IDH2R172, DNMT3A, TET2 and RHOAG17V were 
available.6  
ConsensusClusterPlus package for R 14 was used to determine the significance and 
robustness of natural grouping of patients based on selected transcriptional data, using 
Ward and Euclidean as linkage and distance metrics, respectively.  
CIBERSORT analysis was performed as previously described, using standard 
procedure and LM22 signature.15 The CIBERSORT different contribution for each signature 
was then tested by pairwise.wilcox.test R function. Benjamini-Hochberg correction was used 
for multiple testing adjustment. The pathway enrichment analysis was performed using 
different modalities. The tmod R package was used on limma-derived signatures to decipher 
whether clusters deregulate blood cell-associated transcriptional modules described by 
Chaussabel et al.16 and by Li et al.,17 according to the procedure described by Weiner et al.18 
The full analysis process written in R is provided in Supplementary Data at 
https://github.com/emacgene/PTCL. 
Data from 34 previously published RNAseq samples have been imported upon 
obtainment of accession to dbGap dataset #phs000689.v1.p1.9 RNAseq mapping and 











read counts were processed using iRAP pipeline,19 and the RNAseq raw expression 
data were normalized as previously described.20 
 
Results 
According to the most recent updates in the T-cell lymphoma classification1 and the gene-
expression based classification criteria as in Iqbal et al,21 we generated the whole 
transcriptional profile of a dataset including 127 AITL, 144 PTCL-NOS, 56 ALK+ (Anaplastic 
Large-Cell Lymphoma) ALCL, 96 ALK- ALCL, 21 Adult T-Cell Lymphoma (ATLL), 59 NK/T-
cell lymphomas (Figure 1a, from here on named as “molecular classification”). Both 
unsupervised hierarchical clustering and principal component analysis on the most variable 
genes (exceeding the mean an average 2-fold across the dataset) showed that the known 
entities, such as ALK+ ALCLs and ATLL were associated with markedly distinct signatures; 
notably, the transcriptional portrait of AITL and PTCL-NOS displayed a considerable overlap 
(Figure 1b-c). For completeness, the stability of the identified clusters was tested to unravel 
the most relevant overlapping and to describe the phenotypes characterized by overall 
uniform transcriptional pattern; the whole confusion matrix was reported in Supplementary 
Data. Overall, our meta-analysis of the largest gene-expression profiling dataset tested to 
date showed that the consensus between transcriptomic analysis and histology is still 
imperfect, opening the field for the search of additional features that could improve 
diagnostic accuracy. 
 
Definition of gene signature associated with molecular classification and mutational status 
To search for additional features that could better define the AITL and PTCL-NOS 
entities, we investigated whether recurrent mutations or clinical features might correlate with 
a specific transcriptional pattern that could be used for stratification purposes. To this aim, 
we adapted a recently published analysis13 to a set of 39 AITL and 14 PTCL-NOS cases for 
which mutational data for IDH2R172, DNMT3A, TET2 and RHOAG17V were available.6 This 
analysis allowed the creation of a linear model that associated gene-by-gene expression to 











putative predictor variables, namely the molecular classification histotype, mutations, age 
and gender of each patient. We identified 221 modulated genes across the training dataset 
at false discovery rate (FDR) <1% (Figure 1a), among which 30 of them emerged as 
significantly associated to one distinct variable (Figure 2b). Gender selectively impacted 14 
genes located on the X or Y chromosomes, which were discarded from further analysis. 
Histotype and IDH2R172 mutations specifically impacted the expression of 13 and 3 genes, 
respectively, while notably the mutational status of RHOAG17V, TET2 and DNMT3A (Figure 
2b) were not associated with any distinct gene expression change. The 3 genes associated 
with IDH2R172 mutation were ID2, NETO2 and SLC5A3. Three out of 13 histotype-associated 
genes were also reported in a previous large gene expression signature that discriminates 
PTCL-NOS and AITL (ROBO1, ARHGEF10 and EFNB2)3. Based on these findings, we 
wondered whether a minimal signature including these 16 genes might effectively stratify 
AITL and PTCL-NOS cases. A leave-one-out cross validation (LOOCV) procedure run using 
linear discriminant analysis22 supported the robustness of this 16-gene model, indicating 
overall 86.4% accuracy (sensitivity 86.9%; specificity 85.9%) in discriminating AITL from 
PTCL-NOS.  
Prompted by the evidence that this small 16-gene signature robustly stratified these 
two entities, we hypothesized that combining this signature with the previously described 3-
gene ALK- ALCL signature22 may lead to a 19-gene model able to improve the stratification 
of all major PTCL entities (ALK- ALCL, PTCL-NOS and AITL). Again, a LOOCV procedure 
indicated that the 19-gene model was robust (overall accuracy 80.1%). 
 
Assessment of the 19-gene signature expression level in an independent cohort 
To test the reproducibility of the signature, we analyzed the expression levels of the 
genes for which data were available in 30 PTCL-NOSs cases (11 AITL, 11 PTCL-NOS, 8 
ALK- ALCL) from a previously published RNAseq dataset.9 To this aim, we first classified the 
samples according to the described molecular classification using a LOOCV procedure and 
the published gene signature3 that has been used to test build the expression/mutation 











model (Supplementary data). Of the 19 genes included in our model, 17 were mapped and 
detected in the 30 samples, overall retaining significant difference in the group distribution 
(Supplementary Figure 2).3,22  
 
Patients’ stratification according to the 19-gene signature 
To further investigate the significance and robustness of natural grouping of patients 
based on selected 19-gene transcriptional data, we applied the ConsensusClusterPlus 
package to our original cohort, using Ward and Euclidean as linkage and distance metrics, 
respectively. This analysis led to the recognition of a minimum of five distinct subsets at the 
highest significance (Figure 2c), whose features are summarized in Table 1. The first group 
(C-1; 87 cases) mostly included AITL samples (93%; 81/87) enriched for IDH2R172 (16/36; 
44%) and RHOAG17V (23/29; 79%) mutations. The second (C-2; 103 samples), where the 19-
gene expression pattern resembled that in C-1 but at lower levels, included samples 
annotated either as PTCL-NOS (64/103; 62%) or AITL (33/103; 32%). Interestingly, in the C-
2 group, despite the IDH2R172 mutation was detected in only one out of 23 cases where the 
mutational status was known (p=0.001 if compared to C-1), a very high prevalence of 
RHOAG17V mutations was observed (15/29; 52%). RHOAG17V mutation occurrence was, 
moreover, significantly higher than what observed in cluster 3 and 4 (p<0.005). Despite their 
high prevalence, RHOAG17V mutations had a lower impact on transcription (as evidenced by 
Figure 2b), likely because they were prevalently detected at sub-clonal level in a significant 
fraction of these cases, and this may explain their specific lower impact on transcription (as 
evidenced by Figure 2b). The third cluster (C-3; 32 samples) included patients who showed 
the lowest 19-gene expression levels overall, and an equal admixture of the three main 
PTCL entities. Group 4 (C-4; n=63) included mainly PTCL-NOS (52/63; 82%), showing low 
prevalence of RHOAG17V and TET2 mutations compared either to C-1 (p<0.0001 and 
p=0.0002, respectively) or C-2 (p=0.005 and 0.03 respectively). In the last cluster (C-5; 
n=55) ALK- ALCL cases (47/69; 68%) were over-represented, confirming the strong 











association between these lymphomas and the previously published expression pattern of 
TNFRSF8, BATF3 and TMOD1.22  
 
Functional annotation, gene-expression based estimation of microenvironment composition 
and clinical relevance of 19-gene associated groups 
To decipher whether these clusters might be characterized by common 
transcriptional behavior, we first investigated if they showed pathway enrichments. To this 
aim, tmod R package was used on limma-derived signatures to query whether clusters 
deregulated specific transcriptional modules associated with distinct blood cells. This 
analysis suggested significant enrichment of B-cell related pathways in C-1 and C-2, 
whereas C-5 showed enrichment for stimulated CD4+ T cells associated pathways, and 
significantly lower involvement of T-cell differentiation and T-cell activation pathways 
(Supplementary Figure 3). To understand whether this might be the consequence of a 
somehow unbalanced microenvironment composition, we then applied CIBERSORT,23 an 
analytical tool developed to provide an estimation of the abundances of specific cell types in 
a mixed cell population based on gene expression data. CIBERSORT analysis was 
performed as previously described, using standard procedure and the LM22 signature 
(Supplementary Figure 4).23 Notably, we observed a prevalence of pathways associated 
with plasma cells in C-1 and C-2, in agreement with the notion that AITL are often enriched 
in B-cells/plasma cells.3 Also of interest, CIBERSORT analysis evidenced a slight 
prevalence of activated NK cell-like profiles in the C-3 cluster, overall suggesting that this 
cluster might be considered a spurious entity due to partial contamination of NK-associated 
signatures; and higher presence of activated memory T-CD4 lymphocytes in the ALK- ALCL 
cluster (C-5), supporting previous evidences that CD4+ expression characterizes almost all 
the anaplastic lymphomas,24 and is not exclusively dependent on the ectopic expression of 
the ALK protein. 
Finally, we tested whether the five clusters were associated to different prognosis in 
the 239 patients for whom outcome data were available. No significant global differences in 











prognosis could be appreciated; however, a marginally poorer prognosis was identified in C-
3 patients (p=0.0614, Supplementary Data and Supplementary Figure 5).   
 
Discussion 
Gene expression has emerged as one of the most robust and reliable approaches to 
differentiate human lymphomas. This has also been the case of T-cell lymphomas, where 
gene expression-based strategies have allowed the distinction of closely related entities like 
AITL and PTCL-NOS. 3,21,22,25-28 However, gene expression profiling from formalin fixed 
paraffin embedded samples has known technical artifacts29 and analysis is not standardized. 
Thus, the molecular/expression stratification of PTCL has not entered yet into routine clinical 
practice. Recently, novel technologies (e.g. nanoString) have provided reproducible and 
feasible quantification of specific transcripts from FFPE samples, particularly for diffuse large 
B-cell lymphoma.30-32 However, this approach has not yet been tested in PTCL, likely 
because a short and robust list of differentially expressed genes has not emerged yet.  
To bridge this gap, we performed a meta-analysis of a large PTCL series, assessing 
the molecular profile of the main PTCL subgroups and defining a manageable list of 
significant differentially expressed genes. By integrating transcriptional and NGS data, we 
were able to discover the transcriptional impact of the recurrent mutations in AITLs and 
PTCL-NOSs. Interestingly, TET2, DNMT3A, RHOAG17V mutations were not associated with a 
distinct gene expression signature. In particular, RHOAG17V mutations were detected at sub-
clonal level in a significant fraction of these cases (43%)6 and this may explain its low impact 
on transcription6. On the other hand, TET2 and DNMT3A mutations are likely clonal 
mutations arising from hematopoietic stem cells involved in clonal hemopoiesis;33-35 
therefore, these mutations could induce gene expression signatures shared by other PTCL 
subtypes and masked by the molecular classification, subsequently limiting its extraction 
through our statistical process. Conversely, in line with a previous report,6 the IDH2R172 
mutation significantly correlated with a distinct expression signature independently from the 
molecular subgroup. Through the integration pathological data, transcriptional and NGS 











analyses we then defined a short list of 19 genes whose differential expression divided the 
samples into 5 clusters, strongly associated with distinct PTCL entities. Specifically, C-1 and 
C-2 were characterized by most of the AITL hallmarks. In addition, despite their limited gene 
expression impact, the great majority of RHOAG17V and TET2 mutations were grouped 
together, confirming their potential utility in the diagnostic process of these lymphomas. A 
significant fraction of PTCL-NOSs were included in these two “AITL clusters”. Most of these 
cases showed high prevalence of RHOAG17V and TET2 mutations and expressed some 
distinct, and in part previously reported, AITL-associated genes. Unfortunately, missing 
paired molecular/genomic data in a significant portion of the dataset prevented the possibility 
to define a robust and definitive molecular classifier able to dissect this “grey zone” of PTCL 
classification.  
Nonetheless, 6 of the 16-gene signature were previously described as T Follicular 
Helper (TFH)-phenotype related8. Unfortunately, no cases could be a priori classified as 
nodal PTCL-NOS with (TFH) phenotype, since WHO has introduced this category after the 
original studies were performed1 and phenotypic data were not available. However, these 6 
genes were significantly overexpressed in C-1 and C-2, in line with the recent WHO 
classification where PTCL TFH and AITL are grouped under an unique umbrella category.  
Finally, based both on the present and recently published3,21,36 data, PTCL-NOS 
cases in cluster C-4 likely may represent a distinct biologically entity. In line with previous 
findings,4 cases within this cluster had a distinct genotypic and transcriptional pattern, mostly 
characterized by significant enrichment in downregulated genes.  
Taken together, our analyses based on a small 19-gene model offered a more 
insightful perspective of the dissection of the complex nodal PTCL entities. We suggest that, 
in the future, the integration of transcriptional and genotypic data may improve the 
identification of clinic-pathological entities, contributing to the current diagnostic approach of 
PTCLs and laying the basis for effective treatments through the identification of specifically 
and recurrently dysregulated pathways.  
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Figure 1. (a) Molecular composition of the gene expression cohort (503 tumor cases); 
unsupervised hierarchical clustering (b) and Principal Component Analysis (c) on the entire 
series.  
 
Figure 2. (a) Distribution of the variance of expression levels across genes explained by 
clinical, molecular and genetic alterations (f-test; FDR<1%; 221 samples). (b) Statistically 
significant mutation expression interaction terms (f-test; FDR<1%), for each alteration and 
clinical variable. The associated logarithmic expression fold change is indicated by colour. 
(c) Heatmap of the 19-genes model including all PTCL-NOS, AITL and ALK- ALCL cases 
(340 samples), stratified according to the cluster determined by the ConsensusClusterPlus R 
function. 
  















Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 
Histology 
    
 
   AITL 81 (93%) 33 (32%) 8 (25%) 5 (8%) 0 
   ALCL ALK-neg 3 (3.5%) 6 (6%) 7 (22%) 6 (9.5%) 47 (88%) 
   PTCL-NOS 3 (3.5%) 64 (62%) 17 (53%) 52 (82.5%) 8 (12%) 
Gender 
    
 
   Female 26 (37%) 31 (41%) 4 (33%) 20 (41%) 8 (26%) 
   Male 45 (63%) 43 (59%) 8 (67%) 28 (59%) 22 (74%) 
Age (Median) 64 (33-87) 62 (19-88) 60 (35-97) 62 (21-87) 59 (31-80) 
TET2 
    
 
   MUT 26 (84%) 19 (65%) 0 (0%) 6 (32%) 0 
   WT 5 (16%) 10 (35%) 1 (100%) 13 (68%) 0 
DNMT3A 
    
 
   MUT 13 (42%) 9 (31%) 0 3 (16%)  0 
   WT 18 (58%) 20 (69%) 1 (100%) 16 (84%) 0 
RHOA 
    
 
   MUT 23 (79%) 15 (51%) 0 2 (10.5%) 0 
   WT 6 (21%) 14 (49%) 1 (100%) 17 (89.5%) 0 
IDH2 
    
 
   MUT 16 (45%) 1 (4%) 0 1 (33%) 0 
   WT 20 (55%) 22 (96%) 0 2 (67%) 0 
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